Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZE50-0134 first-in-human study in healthy volunteers
NCT06787131Phase 1Completed
- Sponsor
- Lomond Therapeutics
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lonitoclax (13 arms), sponsored by Lomond Therapeutics. Primary endpoints: Plasma Pharmacokinetics of ZE50-0134 and Plasma Pharmacokinetics of ZE50-0134 with and without Rabeprazole. Started May 2024; status: completed.
02
Drugs
lonitoclax
Beyond the preview
Go deeper on NCT06787131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787131.